Psychopharmacologia

Editorial Board

D. Bovet, Sassari · J. O. Cole, Boston · J. Delay, Paris · J. Elkes, Baltimore
M. Hamilton, Leeds · H. Isbell, Lexington · E. Jacobsen, København
M. E. Jarvik, New York · S. S. Kety, Boston · C. Kornetsky, Boston · E. Rothlin, Basel
M. Shepherd, London · Hannah Steinberg, London · E. Strömgren, Risskov
A. Wikler, Lexington

Managing Editors

J. O. Cole · M. Hamilton · E. Jacobsen · C. Kornetsky

Advisory Board

Neurophysiologia

F. Bremer, Bruxelles
J. C. Eccles, Amherst
A. Fessard, Paris
G. W. Harris, London
G. Moruzzi, Pisa
J. Z. Young, London

Neuropharmacologia

P. B. Bradley, Birmingham
A. Carlsson, Göteborg
H. Coper, Berlin
E. Domino, Ann Arbor
D. Efron, Chevy Chase
U. S. von Euler, Stockholm
W. S. Feldberg, London
S. Garattini, Milano
L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto
S. Irwin, Portland
K. F. Killam, Palo Alto
I. P. Lapin, Leningrad
L. Lasagna, Baltimore
E. Marley, London
W. R. Martin, Lexington
H. O. Schild, London
F. Sjöqvist, Stockholm
F. Sulser, Nashville
A. Weissman, Groton, Conn.
E. Zaimis, London

Neurochimia

S. Barondes, La Jolla
H. Blaschko, Oxford
J. Glowinski, Paris
D. Richter, Epsom
R. Rodnight, London
S. Udenfriend, Bethesda
H. Weil-Malherbe, Washington

Neurologia

H. Gastaut, Marseille
P. van Gehuchten, Bruxelles

Psychiatria

J. Angst, Zürich
H. Brill, New York
P. Deniker, Paris
P. Dick, Genève
F. Flügel, Erlangen
H. Hippius, München
J. Jaffe, Chicago
G. Klerman, Boston
N. S. Kline, Orangeburg
M. H. Lader, London
A. J. Lewis, London
P. Pichot, Paris
K. Rickels, Philadelphia
J. Schildkraut, Boston
J. R. Smythies, Edinburgh
W. A. Stoll, Zürich
O. Vinar, Praha

Psychologia

P. Carlton, New Brunswick
P. B. Dews, Boston
A. DiMascio, Boston
H. J. Eysenck, London
S. Fisher, Boston
S. C. Goldberg, Chevy Chase
S. Grossman, Chicago
H. Hanson, West Point
H. E. Hill, Lexington
C. R. B. Joyce, Basel
M. Katz, Chevy Chase
R. Kelleher, Boston
V. Laties, Rochester
A. Latz, Tel-Aviv
A. Lubin, Leeds
A. E. Maxwell, London
J. L. McGaugh, Irvine
A. Mirsky, Boston
D. Overton, Philadelphia
V. J. Polidora, Davis
R. Russell, Irvine
L. Stein, Philadelphia
A. Summerfield, London
T. Thompson, Minneapolis
O. Zangwill, Cambridge

Volume 20 · 1971

SPRINGER-VERLAG · BERLIN · HEIDELBERG · NEW YORK

With the acceptance of a manuscript for publication, the publishers acquire the sole copyright for all languages and countries, including all rights of photocopying or reproduction by any other method.

The use of registered names, trademarks etc. in this journal does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and, therefore, free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Berlag Berlin Heidelberg 1971

Contents

Page

AHLENIUS, S., ERIKSSON, H., LARSSON, K., MODIGH, K., SÖDERSTEN, P.: Mating Behavior in the Male Rat Treated with p-Chlorophenylalanine Methyl Ester Alone and in Combination with Pargyline 383

BAUM, M., see JAFFE, P. G. 97

BENEŠOVÁ, O., NÁHUNEK, K.: Correlation between the Experimental Data from Animal Studies and Therapeutical Effects of Antidepressant Drugs 337

BERGH, R. VAN DEN, see PRAAG, H. M. VAN, et al. 66

BERNASCONI, S., see VALZELLI, L. 91

BÍLKOVÁ, J., RADIL-WEISS, T., BOHDANECKÝ, Z.: The Influence of Low LSD Dose Administration during Sleep in Rats 395

BJÖRKSTRAND, P.-Å., DUREMAN, I.: Relaxation Transfer in Electrodermal Activity as Affected by a New Minor Tranquillizer (4306CB) 288

BLUM, K., see GELLER, I., et al. 355

BOGGAN, W. O., FREEDMAN, D. X., LOVELL, R. A., SCHLESINGER, K.: Studies in Audiogenic Seizure Susceptibility 48

BOHDANECKÝ, Z., see BÍLKOVÁ, J., et al. 395

BOSMA, E., see PRAAG, H. M. VAN, et al. 66

BUREŠ, J., see BUREŠOVÁ, O. 57

BUREŠOVÁ, O., BUREŠ, J.: The Effect of Prolonged Cortical Spreading Depression on Consolidation of Visual Engrams in Rats 57

CLARK, G., KOESTER, A. G., PEARSON, D. W.: Exploratory Behavior in Chronic Disulfoton Poisoning in Mice 169

COOPER, H. P., see FIBIGER, H. C., et al. 366

COULTER, J. D., see LESTER, B. K., et al. 280

COVI, L., see RICKELS, K., et al. 128

COWDEN, L. C., see LESTER, B. K., et al. 280

DALGLISH, F. W., see RUSSELL, R. W., et al. 32

DALLEMAGNE, GH.: Traitement prolongé à la morphine chez le rat: interaction drogue/comportement dans des conditionnements sous contrôle aversif . . 77

DAVID-REMACLE, M., see GIURGEA, C., et al. 160

DELINI-STULA, A.: Drug-Induced Suppression of Conditioned Hyperthermic and Conditioned Avoidance Behavior Response in Rats 153

DUREMAN, I., see BJÖRKSTRAND, P.-Å. 288

EFRON, D. H., see SCHILDKRAUT, J. J. 191

ENGEL, J., HANSON, L. C. F., ROOS, B.-E.: Effect of Elektroshock on 5-HT Metabolism in Rat Brain 197

ERIKSSON, H., see AHLENIUS, S., et al. 383

EVANGELISTA, A. M., IZQUIERDO, I.: The Effect of Pre- and Post-Trial Amphetamine Injections on Avoidance Responses of Rats 42

FÄHSE, CH., see MATTHIES, H., et al. 10

FIBIGER, H. C., LYNCH, G. S., COOPER, H. P.: A Biphasic Action of Central Cholinergic Stimulation on Behavioral Arousal in the Rat 366

FIEVE, R. R., MELTZER, H. L., TAYLOR, R. M.: Rubidium Chloride Ingestion by Volunteer Subjects: Initial Experience 307

FREEDMAN, D. X., see BOGGAN, W. O., et al. 48

FUNDERBURK, W. H., see JOHNSON, D. N., et al. 1

Page

Geller, I., Hartmann, R., Blum, K.: Effects of Nicotine, Nicotine Monomethiodide, Lobeline, Chlordiazepoxide, Meprobamate and Caffeine on a Discrimination Task in Laboratory Rats 355
Gershon, S., see Sanghvi, I., et al. 118
Giurgea, C., Lefevre, D., Lescrenier, C., David-Remacle, M.: Pharmacological Protection against Hypoxia Induced Amnesia in Rats 160

Han, H., see Itil, T., et al. 230
Hanson, L. C. F., see Engel, J., et al. 197
Hartmann, R., see Geller, I., et al. 355
Henriksson, B. G., Järbe, T.: Effects of Diazepam on Conditioned Avoidance Learning in Rats and Its Transfer to Normal State Conditions 186
Herr, F., see Voith, K. 253
Hsu, W., see Itil, T., et al. 230

Irwin, S., Kinohi, R., Van Sloten, M., Workman, M. P.: Drug Effects on Distress-Evoked Behavior in Mice: Methodology and Drug Class Comparisons 172
Itil, T., Keskiner, A., Han, H., Hsu, W., Ulett, G.: EEG Changes after Fluphenazine Enanthate and Decanoate Based on Analog Power Spectra and Digital Computer Period Analysis 230
— see Saletu, B., et al. 242
Izquierdo, I., see Evangelista, A. M. 42

Järbe, T., see Henriksson, B. G. 186
Jaffe, P. G., Baum, M.: Increased Resistance-to-Extinction of an Avoidance Response in Rats Following the Administration of Hashish Resin . . . 97
Jarvis, M. J., Lader, M. H.: The Effects of Nitrous Oxide on the Auditory Evoked Response in a Reaction Time Task 201
Johnson, D. N., Funderburk, W. H., Ward, J. W.: Effects of Fenfluramine on Sleep-Wakefulness in Cats 1
Jones, J., see Saletu, B., et al. 242

Keskiner, A., see Itil, T., at al. 230
Kinohi, R., see Irwin, S., et al. 172
Kleinrok, Z., Żebrowska-Łupina, I.: Central Action of Phentolamine Administered Intraventricularly in the Rat 348
Koester, A. G., see Clark, G., et al. 169
Kopin, I. J., see Kvetňanský, R., et al. 22
Krivanek, J. A.: Facilitation of Avoidance Learning by Pentylenetetrazol as a Function of Task Difficulty, Deprivation and Shock Level 213
Kumar, R., see Stolerman, I. P., et al. 321
Kvetňanský, R., Silbergeld, S., Weise, V. K., Kopin, I. J.: Effects of Restraint on Rat Adrenomedullary Response to 2-Deoxy-D-Glucose . . . 22

Lader, M. H., see Jarvis, M. J. 201
Larsson, K., see Ahlenius, S., et al. 383
Lefevre, D., see Giurgea, C., et al. 160
Lescrenier, C., see Giurgea, C., et al. 160
Lester, B. K., Coulter, J. D., Cowden, L. C., Williams, H. L.: Chlorpromazine and Human Sleep 280
Lietz, W., see Matthies, H., et al. 10
Lipman, R. S., see Rickels, K., et al. 128
Lovell, R. A., see Boggan, W. O., et al. 48
Lynch, G. S., see Fibiger, H. C., et al. 366

Matthies, H., Fähse, Ch., Lietz, W.: Die Wirkung von RNS-Präcursoren auf die Erhaltung des Langzeitgedächtnisses 10
— see Ott, T. 16
Meltzer, H. L., see Fieve, R. R., et al. 307
Miller, D., see Wikler, A., et al. 103

Page

Mock, J. E., see Rickels, K., et al. 128
Modigh, K., see Ahlenius, S., et al. 383

Náhunek, K., see Benešová, O. 337
Nordin, G., Ottosson, J.-O., Roos, B.-E.: Influence of Convulsive Therapy on 5-Hydroxyindoleacetic Acid and Homovanillic Acid in Cerebrospinal Fluid in Endogenous Depression 315
Norrell, H., see Wikler, A., et al. 103

Ott, T., Matthies, H.: Die Wirkung von Orotsäure auf die durch elektrokonvulsiven Schock ausgelöste retrograde Amnesie 16
Ottosson, J.-O., see Nordin, G., et al. 315
Overstreet, D. H., see Russell, R. W., et al. 32

Park, L. C., see Rickels, K., et al. 128
Pearson, D. W., see Clark, G., et al. 169
Pescor, F. T., see Wikler, A., et al. 103
Praag, H. M. van, Schut, T., Bosma, E., Bergh, R. van den: A Comparative Study of the Therapeutic Effects of Some 4-Chlorinated Amphetamine Derivatives in Depressive Patients 66

Radil-Weiss, T., see Bílková, J., et al. 395
Rickels, K., Lipman, R. S., Park, L. C., Covi, L., Uhlenhuth, E. H., Mock, J. E.: Drug, Doctor Warmth, and Clinic Setting in the Symptomatic Response to Minor Tranquilizers 128
Roos, B.-E., see Engel, J., et al. 197
— see Nordin, G., et al. 315
Russell, R. W., Vasquez, B. J., Overstreet, D. H., Dalglish, F. W.: Effects of Cholinolytic Agents on Behavior Following Development of Tolerance to Low Cholinesterase Activity 32

Saletu, B., Saletu, M., Itil, T., Jones, J.: Somatosensory Evoked Potential Changes during Thiothixene Treatment in Schizophrenic Patients 242
Saletu, M., see Saletu, B., et al. 242
Sanghvi, I., Urquiaga, X., Gershon, S.: Exploration of the Anti-Depressant Potential of L-DOPA 118
Schildkraut, J. J., Efron, D. H.: The Effects of Δ^9-Tetrahydrocannabinol on the Metabolism of Norepinephrine in Rat Brain 191
Schlesinger, K., see Boggan, W. O., et al. 48
Schrold, J., Squires, R. F.: Behavioural Effects of d-Amphetamine in Young Chicks Treated with p-Cl-Phenylalanine 85
Schut, T., see Praag, H. M. van, et al. 66
Senault, B.: Influence de l'isolement sur le comportement d'agressivité intraspécifique induit par l'apomorphine chez le rat 389
Silbergeld, S., see Kvetňanský, R., et al. 22
Sloten, M., Van, see Irwin, S., et al. 172
Södersten, P., see Ahlenius, S., et al. 383
Squires, R. F., see Schrold, J. 85
Steinberg, H., see Stolerman, I. P., et al. 321
Stolerman, I. P.: Analysis of the Acquisition and Extinction of Food-Reinforced Behaviour in Rats after the Administration of Chlorpromazine . . 266
— Kumar, R., Steinberg, H.: Development of Morphine Dependence in Rats: Lack of Effect of Previous Ingestion of Other Drugs 321
Sulman, F. G., see Weller, C. P. 299

Taylor, R. M., see Fieve, R. R., et al. 307

Uhlenhuth, E. H., see Rickels, K., et al. 128
Ulett, G., see Itil, T., et al. 230
Urquiaga, X., see Sanghvi, I., et al. 118

Valzelli, L., Bernasconi, S.: Differential Activity of Some Psychotropic Drugs as a Function of Emotional Level in Animals 91

Page

VASQUEZ, B. J., see RUSSELL, R. W., et al. 32
VOITH, K., HERR, F.: The Effect of Various Antidepressant Drugs upon the Tetrabenazine-Suppressed Conditioned Avoidance Response in Rats . . . 253

WARD, J. W., see JOHNSON, D. N., et al. 1
WEISE, V. K., see KVETŇANSKÝ, R., et al. 22
WELLER, C. P., SULMAN, F. G.: Activity of Major Analgesics on Motor Nociceptive Responses in Decerebrate Mice 299
WIKLER, A., PESCOR, F. T., MILLER, D., NORRELL, H.: Persistent Potency of a Secondary (Conditioned) Reinforcer Following Withdrawal of Morphine from Physically Dependent Rats 103
WILLIAMS, H. L., see LESTER, B. K., et al. 280
WORKMAN, M. P., see IRWIN, S., et al. 172

ŻEBROWSKA-ŁUPINA, I., see KLEINROK, Z. 348

Indexed in Current Contents

Subject Index

Addiction 103
Adrenomedullary response 22
Adrenomimetic effect 337
Acetylcholinesterase 169
Aggressive behavior 85, 91, 172, 389
Alcohol 172, 321
Amine synthesis 319
Amitriptyline 338
Amnesia 160
Amphetamines 1, 42, 85, 253, 348, 387
— chlorinated 66
Amylobarbitone 321
Analgesimetry 299
Anise-flavor 103
Anticholinergic action 337, 366
Antidepressants 66, 93, 118, 153, 253, 318, 337
Antinicotine 337
Antiphysostigmie 337
Antireserpine 337
Antitetrabenazine 337
Antitremorine 337
Anxiety neurosis 128
Anxiolytics 153
Apomorphine 389
Aspirin 153
Atropine 32, 42
Audiogenic seizures 48
Auditory reaction time 201
Avoidance conditioning 42, 77, 97, 153, 186, 213, 253

Behavior 32, 85, 91, 118, 153, 169, 172, 191, 307, 366, 383, 389
Benzodiazepines 93, 153
Benzoquinolizine derivative 253
Biogenic amines 48
Body temperature 366
Butriptyline 253
Butyrophenones 93

Caffeine 355
Cannabis 321
Catecholamines 191, 253, 348
Catron 52
Cats 1
Cerebrospinal fluid 315
Chickens 85
Chlordiazepoxide 128, 172, 321, 355
Chloride, rubidium 307
4-Chloro-amephetamine 66
4-Chloro-N-methylamphetamine 66
p-Chlorphenylalanine methyl ester 383
Chlorpromazine 153, 266, 280
Cholinergic stimulation 366
Cholinergic system 32
Cholinesterase activity 32
Cocaine 321
Conditioned avoidance behavior 153, 186
Conditioned hypothermia 153
Conditoning 42, 77, 153, 160, 253
Consolidiation 10, 16, 57

Convulsive therapy 16, 197, 315
Cortical spreading depression 57

D-amphetamine 253
Decanoate, fluphenazine 230
Decerebrate mice 299
2-Deoxy-D-glucose 22
Depression 57, 66, 118, 307, 315
Desiprimamine 93, 153, 338
Desmethylimipramine 253
Dexamphetamine 321
Diazepam 186
Dibenzepine 338
3,4-Dihydroxyphenylalanine 52
Diisopropyl fluorophosphate 32
Discrimination pattern 57
— training 10, 17, 355
Dissociation 266
Distress arousal 172
Disulfoton 169
Doctor-warmth 128
Dogs 118
Dopamine 118, 253
Dopamine-B-hydroxylase 22
Drug dependence 103, 321
Drug-drive interaction 213
Drug effects 172
Drug interactions 77, 321

EEG 230, 242, 280, 307, 316, 395
EKG 309
Electrotroconvulsive shock 16, 197
— therapy 315
Electrodermal activity 288
Electrolyte 307
EMG 1
Emotional level 91
Enanthate, fluphenazine 230
EOG 1
Ethyl alcohol 172
Etonitazene 103
Evoked potential 201, 242
Exploratory behavior 169
Extinction 10, 16, 97, 266

Fencanfamine 93
Fenfluramine 1, 93
Fighting 172
Flurothyl convulsive therapy 316
Fluphenazine decanoate 230
Fluphenazine enanthate 230
Foot shock 172

Glucose, 2-Deoxy-D 22
Genetics 48

Hashish 97
Hippocampal theta activity 395
Homovanillic acid 315

Human ingestion 307
Human subjects 66, 128, 201, 230, 242, 280, 288, 307, 315, 337
5-Hydroxyindoleacetic acid 197, 315
5-Hydroxytryptamine 66, 85, 197, 253, 348
5-Hydroxytryptophan 52
Hypoxia 160

Imiprimamine 85, 93, 118, 153, 172, 253, 318, 338
Immobilization stress 22
Iproniazid 253
Isolation 91, 389

L-DOPA 118
Learning 160, 186, 266
— facilitation 213
Lithium 307
Lobeline 355
Locomotor activity 172, 348, 366
Long-term memory 10, 16
LSD 395
Lu 3-010 253
Lumbal puncture 316

Manic-depressive 308
MAO (monoamine oxidase) 383
— inhibitors 67, 253
Marijuana 191
Mating behavior 383
Melitracine 338
Memory 10, 16, 57, 160, 186
Meprobamate 128, 153, 355
Metabolism 307
Methamphetamine 1, 172
Methohexital narcosis 316
Methotrimeprazine 299
Methylatropine 32
Methylphenidate 93, 253
Methylscopolamine 373
Mice 48, 91, 169, 172, 213, 299
Monamine metabolites 315
Mood elevation 66
Morphine 77, 103, 153, 299, 321
Motoricity 66
Motor nociception 299
Multiple response phenomenon 288
Muricide reaction 91
Muscarinic, non- 380

Neuroleptic drugs 93, 153
Neurotransmitter substances 322
Nicotine 338
— monomethiodide 355
Nitrous oxide 201
Noradrenalin 337, 348
Norepinephrine 191, 253

Normetanephrine 307
Northiadene 338
Nortriptylene 338

Operant conditioning 32, 160, 266, 355
Opioids 321
Orotic acid 10, 16

Paragyline 253, 383
P-Cl-Phenylalanine 85
Pentazocine 299
Pentobarbitol 172
Pentylenetetrazol 213
Perphenazine 172
Pethidine 322
Phenobarbitone 322
Phentolamine 153, 348
Phenylethanolamine-N-methyl-transferase 22
Physostigmine 338, 366
Pilocarpine 366
Piracetam 160
Placebo 128
Plasma level 307
Positive reinforcement 266
Potassium 308
— chloride 57
Primates 310
Priming 48
Probenecid 315
Protein synthesis 322
Prothiadene 338
Pseudoconditioning 42
Psychochemical therapy 307
Psychotropic drugs 91

Rats 10, 16, 22, 32, 42, 57, 77, 91, 97, 103, 153, 160, 186, 191, 197, 253, 266, 321, 348, 355, 366, 383, 389, 395
Recovery time 172
Relapse 103
Relaxation transfer 288
Reserpine 52, 253
Restraint 22
Retrograde amnesia 16
RNA precursors 10
Rubidium chloride 307

Schizophrenia 242
Scopolamine 366
Secondary reinforcement 103
Self-administration drugs 321
Serotonin 66, 85, 191
Sexual behavior 383
Sleep 72, 280, 395
— paradoxical 1
— slow-wave 1
Somatosensory evoked response 242
Suxamethonium relaxation 316

Tetrabenazine antagonism 253
Δ^9-Tetrahydrocannabinol (THC) 191
Thioridazine 153
Thiothixene 242
Thymoleptics 338
Tolerance, low cholinesterase activity 32
— morphine 77
Tranquilizers 128, 230, 280, 288
— minor 355
Transfer 186
Tricyclic antidepressants 253
Trimepramine 338
Tryptamin 85
Tyrosine hydroxylase 22

Urinary epinephrine 22
— excretion 307

Vocalizing 172

Yohimbine 118

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawing etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wide margin on the left. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
a) the title;
b) the name(s) of the author(s);
c) the name of the laboratory where the work was carried out;
d) a running title of not more than 67 typewriter strokes;
e) footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an English translation of the title.

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the title or authors of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1969).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. *In:* Neuropsychopharmacology. P. B. Bradley, F. Flugle and P. Hoch, *eds.*, vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parantheses, e.g. (Bindra and Mendelson, 1963) or (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Mann (1966) reported that..." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. It must be emphasized that a maximum area available is 108 × 177 mm ($4^1/_4 \times 7''$). Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

First International Congress Munich, 1970

Pharmacognosy and Phytochemistry

Editors: Dr. **H. Wagner**, o. ö. Professor,
Lehrstuhl für Spezielle Pharmakognosie,
Institut für Pharmazeutische Arzneimittellehre
und Professor Dr. Drs. h. c. **Ludwig Hörhammer**,
Direktor des Instituts für Pharmazeutische Arzneimittellehre,
Universität München

With approx. 164 figures
VII, 386 pages. 1971
DM 48,–; US $ 13.20

This volume contains the 16 papers read at the plenary sessions of the 1st Symposium on Pharmacognosy and Phytochemistry, held in Munich in July 1970. The authors are all internationally recognized experts in their fields, many of the results which they report here being based on their own research.
The papers, which are given in unabridged form, complete with chemical structure diagrams, tables and very full literature references, fall under the following main headings: new methods in phytochemical analysis; natural substances of chemical and pharmaceutical interest; synthesis of such substances; biosynthesis of natural substances and chemotaxonomy; pharmacology of natural substances affecting the permeability of the capillaries and the lymphatic system. These themes have been the subject of particularly intensive study in recent years and they are live topics in pharmaceutics, pharmacology and biology. The volume thus constitutes a useful survey of the present state of research and will be an important source of information for scientists interested in the various aspects of natural substances.

Springer-Verlag
Berlin · Heidelberg · New York
München · London · Paris · Tokyo · Sydney

Responsible for advertisements: Edgar Seidler, D-1000 Berlin 15, Kurfürstendamm 237
Springer-Verlag, Berlin, Heidelberg, New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden
© by Springer-Verlag Berlin Heidelberg 1971